Tocilizumab biosimilar (Shanghai Destiny)

The primary purpose of this trial is to investigate the pharmacokinetic characteristics of the test preparation Tocilizumab (IA001 injection), and to compare the main pharmacokinetic parameters of the two preparations by intravenous infusion in healthy male subjects with Tocilizumab injection of Roche Pharma Ltd as the reference preparation, and to evaluate the pharmacokinetic similarity of the two preparations. The secondary purpose is to compare the safety and clinical immunogenicity of the test preparation Tocilizumab (IA001 injection) and the reference preparation Actemra® in healthy male subjects after a single administration of 4 mg/kg.